As a fine of €52.5 million imposed on AstaZeneca is upheld,
Scott Kerr, Intellectual Property (IP) Partner at Semple Fraser, considers whether supplementary protection certificates (SPCs) remain available as a means of extending protection or will be ...
[Published Pharma-Mag - May 01 2013]